Related Experiment Video
Updated: Jun 17, 2026
10:49
Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds
Published on: August 21, 2021
Controlled nitric oxide delivery platform based on S-nitrosothiol conjugated interpolymer complexes for diabetic
1Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario M5S3M2, Canada.
Molecular Pharmaceutics
|December 25, 2009
Summary
A novel nitric oxide (NO) delivery system using interpolymer complexes accelerates diabetic wound healing. This platform provides sustained NO release for over 10 days, enhancing closure in diabetic rat models.
Area of Science:
- Biomaterials Science
- Wound Healing Research
- Drug Delivery Systems
Background:
- Nitric oxide (NO) is crucial for wound healing, but topical application faces challenges due to short release duration and instability.
- Existing NO donors have limitations, hindering effective therapeutic use in conditions like diabetic wounds.
Purpose of the Study:
- To develop a stable, controlled nitric oxide (NO) delivery platform for enhanced diabetic wound healing.
- To overcome the limitations of conventional NO donors through a novel interpolymer complex system.
Main Methods:
- Grafting S-nitrosothiols (RSNOs) onto poly(vinyl methyl ether-co-maleic anhydride) (PVMMA) to form interpolymer complexes with poly(vinyl pyrrolidone) (PVP).
- Characterization of NO release kinetics (>10 days) and complex stability using FTIR and Raman spectroscopy.
- In vivo assessment of the NO delivery system's efficacy in a diabetic rat wound healing model.
Main Results:
- The developed interpolymer complexes demonstrated controlled and sustained release of nitric oxide (NO) for over 10 days.
- The complexes exhibited enhanced stability in solid form compared to free RSNOs.
- A single topical application significantly accelerated wound closure in diabetic rats compared to controls (p < 0.05).
Conclusions:
- The novel NO-releasing interpolymer complexes offer a promising solution for sustained NO delivery.
- This platform effectively enhances wound healing in a diabetic rat model, suggesting potential clinical applications.
- The developed system overcomes key limitations of existing NO donors for improved therapeutic outcomes.
Related Concept Videos
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:28Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:31Diabetic Foot Ulcer
Definition A diabetic foot ulcer (DFU) is a chronic, non-healing wound that develops in individuals with diabetes. It typically occurs on pressure-bearing areas such as the heel, metatarsal heads, or hallux, and carries a high risk of infection and amputation.Pathophysiology • The development of DFUs can be explained by four interconnected mechanisms: neuropathy, ischemia, infection, and impaired wound healing. • Neuropathy is the most common factor. Sensory neuropathy reduces pain perception,...
01:18Transdermal Drug Delivery Systems
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...